Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
11/2000
11/23/2000CA2373191A1 Full-length molecules expressed in human tissues
11/23/2000CA2372926A1 143 human secreted proteins
11/23/2000CA2372549A1 Ox2 receptor homologs
11/23/2000CA2372541A1 Sphingosine kinase enzyme
11/23/2000CA2372119A1 Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily
11/23/2000CA2372102A1 Lawsonia derived gene and related omph polypeptides, peptides and proteins and their uses
11/23/2000CA2371212A1 Differential gene expression in specific regions of the brain in neurodegenerative diseases
11/23/2000CA2369376A1 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer and for prevention of cancer in at-risk subjects
11/23/2000CA2368948A1 Envelope gene-deficient virus vector of paramyxoviridae
11/23/2000CA2368833A1 Molecules expressed in hippocampus
11/23/2000CA2368620A1 Genetic modification of male germ cells for generation of transgenic species and genetic therapies
11/23/2000CA2368593A1 Anti-inflammatory therapy for inflammatory mediated infection
11/22/2000EP1054064A1 Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
11/22/2000EP1054059A1 Novel cDNAs encoding catenin-binding proteins with function in signalling and/or gene regulation
11/22/2000EP1054058A1 Pharmaceutical composition for treatment of Duchenne muscular dystrophy
11/22/2000EP1053751A1 Compositions and methods for treating cell proliferation disorders
11/22/2000EP1053351A1 Novel molecules of the tnf receptor superfamily and uses therefor
11/22/2000EP1053343A2 Targeting of genetic vaccine vectors
11/22/2000EP1053342A2 Nucleic acid delivery vehicles
11/22/2000EP1053341A1 Use of negative regulation elements for nerve-specific expression of transgenes
11/22/2000EP1053332A1 Protein
11/22/2000EP1053325A2 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
11/22/2000EP1053318A2 Cdnas encoding secreted proteins
11/22/2000EP1053316A1 Nucleic acids provided for modulating cellular activation
11/22/2000EP1053313A1 Optimized antisense oligonucleotides complementary to dna methyltransferase sequences
11/22/2000EP1053312A2 Optimization of immunomodulatory properties of genetic vaccines
11/22/2000EP1053309A1 Compositions and methods for wound healing
11/22/2000EP1053308A1 Dendritic enriched secreted lymphocyte activation molecule
11/22/2000EP1053306A1 Secreted proteins and polynucleotides encoding them
11/22/2000EP1053302A2 Expanded and genetically modified populations of human hematopoietic stem cells
11/22/2000EP1053301A1 A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
11/22/2000EP1053251A1 The aiolos gene
11/22/2000EP1053245A1 45 human secreted proteins
11/22/2000EP1053241A1 Novel dimerizing agents, their production and use
11/22/2000EP1053025A2 Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
11/22/2000EP1053024A1 Liposome fusion and delivery vehicle
11/22/2000EP1053023A2 Systemic delivery of serum stable plasmid lipid particles for cancer therapy
11/22/2000EP1053022A2 Sensitizing cells to compounds using lipid-mediated gene and compound delivery
11/22/2000EP1053013A1 Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob
11/22/2000EP1053007A2 Methods and compositions for modulating leptin activity
11/22/2000EP1053002A1 Treatment of bony defects with osteoblast precursor cells
11/22/2000EP0703988B1 Mesothelial cell gene therapy
11/22/2000CN1274387A HCVE mimotopes of hypervariable region 1 and uses
11/22/2000CN1274290A Vaccination by topical application of genetic vectors
11/21/2000US6150340 RNA-dependent amidotransferase from Staphylococcus aureus
11/21/2000US6150338 Delivery and expression of a recombinant vector containing a dna sequence encoding a protein involved in the regulation of smooth muscle tone into a smooth muscle cell
11/21/2000US6150170 Infecting cultured animal cells with live invasive bacteria containing eukaryotic expression cassette; gene is expressed at detectable levels; gene therapy; vaccines
11/21/2000US6150168 Complex containing a binding molecule which non-covalently binds to the nucleic acid and covalently links to a surface ligand and a nuclear ligand; for gene therapy
11/21/2000US6150132 Vector coding polypeptides for the diagnosis and treatment of allergies and atherosclerosis; for the prevention of graft ejection and injuries to stem cell caused by anticarcinogenic agents
11/21/2000US6150116 Transcription factor DP-1 antibody
11/21/2000US6150101 Methods of identifying a composition that alters connective tissue growth factor expression
11/21/2000US6150099 Detecting modulators of transcription factors; incubating transcription factor and modulator in solution, monitor the level of gene expression
11/21/2000US6150093 Unique associated Kaposi's sarcoma virus sequences and uses thereof
11/21/2000US6149936 DNA expression vectors for the use in the gene therapeutic treatment of vascular disorders
11/21/2000US6149922 Vaccine adjuvant and vaccine
11/21/2000US6149911 Method for enhancing the immunogenicity of an immunogenic compound or hapten, and use thereof for preparing vaccines
11/21/2000US6149907 Treatments using sertoli cells
11/21/2000US6149906 Activation of t-lymphocytes and induction of antigen-specific immune responses; preventing, treating various diseases ( viral, bacterial, fungal), botulism toxin, poison ivy, poison sumac
11/21/2000US6149905 Administering a modifying tumor cells from a mammalian subject to express a b7 molecule; preventing or inhibiting metastatic spread of a tumor
11/21/2000US6149903 Suppressing the growth of an epithelial ovarian tumor in a mammal by injecting a genetic engineered vector to an intraperitoneal cavity of the mammal at the site of tumor
11/21/2000US6149902 Manipulation of non-terminally differentiated cells using the notch pathway
11/16/2000WO2000068399A2 Vector-mediated delivery of integrating transposon sequences
11/16/2000WO2000068386A1 Autotaxin variants and uses to treat diseases of metabolism
11/16/2000WO2000068384A2 NOVEL NUCLEIC ACIDS AND PROTEINS WITH p53 ACTIVITY AND ALTERED TETRAMERIZATION DOMAINS
11/16/2000WO2000068380A2 Extracellular matrix and adhesion-associated proteins
11/16/2000WO2000068379A1 Methods for treating tumors using antiangiogenic compounds
11/16/2000WO2000068376A1 Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same
11/16/2000WO2000068361A1 Versican and epithelial-mesenchymal interaction
11/16/2000WO2000068360A1 A histidine kinase, 636 hk, of staphylococcus aureus
11/16/2000WO2000068269A1 Constitutive chimeric receptors, and methods of use thereof
11/16/2000WO2000068261A2 Attenuated microorganisms for the treatment of infection
11/16/2000WO2000068247A2 Serine proteases
11/16/2000WO2000068241A1 Processes for the synthesis of oligomers using phusphoramidite compositions
11/16/2000WO2000067803A1 Compositions and methods for improving learning and memory
11/16/2000WO2000067798A2 Enhanced delivery of nucleic acid-based drugs
11/16/2000WO2000067775A1 Fibroblast growth factor 15
11/16/2000WO2000067762A2 Selenium-containing pro-drugs for cancer therapy
11/16/2000WO2000067761A1 Compositions and methods for identifying antigens which elicit an immune response
11/16/2000WO2000067697A2 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells
11/16/2000WO2000067576A1 Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
11/16/2000WO2000047223A3 Viral vaccine
11/16/2000WO2000043530A3 Stabilisation of compositions comprising non-viral nucleic acid transfer compositions
11/16/2000WO2000043501A3 Ribozymes directed against the catalytic subunit of the human telomerase (htert)
11/16/2000WO2000042179A3 Complex-forming proteins
11/16/2000WO2000041717A3 Chorionic gonadotropin dna vaccines and methods
11/16/2000WO2000040273A3 Treatment of viral diseases using an interferon omega expressing polynucleotide
11/16/2000WO2000039287A3 A. fumigatus acetyl coenzyme-a carboxylase genes and polypeptides and uses thereof
11/16/2000WO2000039285A3 Human glycosylphosphatidylinositol specific phospholipase d variants and uses thereof
11/16/2000WO2000037613A3 Human akt-3
11/16/2000WO2000036118A3 HUMAN CYCLIN-DEPENDENT KINASE (hPNQALRE)
11/16/2000WO2000034468A3 Muc-1 antagonists and methods of treating immune disorders
11/16/2000WO2000029015A3 INFLUENCING OF ANGIGENESIS USING CD66a
11/16/2000WO2000029012A3 Methods of alleviating cancer symptoms
11/16/2000WO2000026247A3 Ikaros isoforms and mutants
11/16/2000WO2000023464A3 Zinc finger binding domains for gnn
11/16/2000WO2000022095A9 Method and apparatus for direct in vivo gene transfer by electrotransfection
11/16/2000WO2000020448A3 Nlk1 -interacting proteins
11/16/2000WO2000014113A3 Method of stimulating prosaposin receptor activity
11/16/2000DE19922407A1 Preparing medicament for treating viral infections, liver diseases or cancer, comprising recombinant parapoxvirus targeted towards specific organs, cells or tissues
11/16/2000DE19919225A1 Tumorassoziiertes Antigen Tumor-associated antigen
1 ... 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 ... 870